- en
- nl
TTO Flanders provides access to the latest technologies and inventions of the Flemish universities and their associated universities of applied science and arts. For the full range of licensing opportunities, please visit the FRIS research portal of the Flemish government.
Here we highlight 10 recent technology offers.
Chromosome abnormalities are very frequent in early human IVF embryos and are considered the main cause of implantation failure and miscarriage. Current detection methods are either unable to capture the full spectrum of chromosomal abnormalities or require DNA from family members, limiting their broader application. APCAD offers an innovative solution by combining chromosome number (CN) with the proportion of maternal copies (%Mat). In doing so, APCAD accurately detects the complete range of chromosome abnormalities without the need for relative DNA, making the method more efficient and reliable for embryo selection.
Client-side rendering of 3D graphical content that is hosted on a remote content server can incur long start-up delays, because the content first needs to be downloaded before it can be rendered locally. UHasselt has therefore developed a progressive network streaming framework for 3D content that lets client devices gradually render a more complete version of the 3D scene while it is being downloaded, similar to how video streaming works on popular platforms like YouTube and Netflix. The framework can be used directly in Web browsers or integrated into 3D engines like Unity.
Current treatments for chronic diseases, such as opioids, have a short duration of action and require high dosages, which increases the risk of side effects and reduces treatment adherence. The VUB Research Group of Organic Chemistry (ORGC) has developed an injectable, thixotropic peptide hydrogel that rapidly recovers and provides sustained drug release. This reduces both the frequency of administration and the likelihood of side effects. The hydrogel is biocompatible, easy to synthesise, and can effectively encapsulate a wide range of therapeutic agents, including proteins and morphine. Thanks to these properties, it holds broad potential for use in medicine and tissue engineering.
The invention presents an innovative approach to solid electrolytes, addressing critical challenges in lithium-ion battery (LIB) performance, manufacturability, and compatibility with battery components. An ionogel based on a liquid electrolyte confined in a solid matrix is a promising type of solid electrolyte. To be used in commercially viable processes, the ionogel should however combine good functional properties, manufacturability and compatibility with the other battery materials. Current state of the art technologies cannot meet all of these criteria. The current innovative solution developed by imo-imomec (the joint research institute of Hasselt University and imec), centers on a specially formulated liquid precursor capable of rapid, controlled solidification into a highly conductive, stable, and compliant solid electrolyte.
The University of Antwerp (TPR) has developed advanced logistics chain cost calculation instruments for interurban and urban transport. This technology enables companies to see which mode or combination of modes is most cost-efficient, both from an operational and a societal point of view.
Bovine mastitis, an inflammation of the cow’s udder that is usually caused by a bacterial infection, is the most important economic disease affecting dairy cattle. Bacteriophage-derived endolysins (“enzy-biotics”) are increasingly gaining attention due to their specificity, high killing efficacy, unlikely resistance development and rapid degradation in the environment. We engineered a novel and performant endolysin, NC5. NC5 has the potential to kill AMR streptococci, also in raw milk, accelerate bacterial killing, kill intracellular streptococci and eradicate streptococci-formed biofilms.
Current antiprotozoal treatments against protozoal infections are often ineffective, require a suboptimal compoundadministration route, face increasing resistance and are endowed with concerns about toxicity (direct and indirect). Therefore, novel treatment options are needed, to treat a large variety of protozoan-caused infections. We have prepared a purine nucleoside platform in the Laboratory for Medicinal Chemistry (Ghent University), based on known and novel sugar- and purine ring scaffolds. We have demonstrated their ability to act as antiprotozoal agents (primarily against trypanosomes, but also other).
We present a tigecyclin repurposing opportunity for metastatic uveal melanoma, an orphan oncology indication with a high unmet clinical need. Tigecyclin is a safe, clinically approved, off-patent glycylcyclin antibiotic. We are looking for a partner to further clinically explore and develop this repurposing opportunity.
We here present the pPUT expression system for high-yield recombinant protein production in Pseudomonas with tight regulation and large scalability potential. By combining a phage-derived transcription module with a two-phase design, pPUT delivers vastly higher yields and broad applicability for industrial biotechnology.
Dive into the research portal and discover all opportunities.